-+ 0.00%
-+ 0.00%
-+ 0.00%

Sinqi Eye Medicine (300573.SZ): First patient enrolled in phase II clinical trial of SQ-22031 eye drops to treat moderate to severe dry eye

Zhitongcaijing·12/09/2025 12:09:13
Listen to the news

Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) announced that today, the SQ-22031 eye drops developed by the company completed “a multi-center, randomized, double-blind, placebo-controlled phase II clinical study evaluating the efficacy and safety of SQ-22031 eye drops in the treatment of moderate to severe dry eye”.

According to the announcement, the SQ-22031 Eye Drops Phase II study was a multicenter, randomized, double-blind, placebo-controlled clinical study. The purpose was to evaluate the efficacy and safety of SQ-22031 eye drops in patients with moderate to severe dry eye, and to analyze and evaluate their immunogenicity and effects on changes in corneal nerve density.